INCB028050

Known as: INCB 028050 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2015
01220102015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
OBJECTIVES To investigate baricitinib (LY3009104, formerly INCB028050), a novel, oral inhibitor of JAK1/JAK2 in patients with… (More)
Is this relevant?
2014
2014
Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule inhibitor of Janus kinase family of… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
2013
2013
Janus kinase (JAK) inhibitors have been developed as anti-inflammatory agents and have demonstrated clinical efficacy in… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases… (More)
Is this relevant?